BTK inhibitor

News

A female palm containing a Rhapsido tablet

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?

News

Lilly trumpets strong result for Jaypirca in CLL at EHA

New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.

News

Roche doubles down on BTK with $2.3bn Nurix deal

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

Rhapsido is first drug cleared for chronic hives disorder SD

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly trumpets strong result for Jaypirca in CLL at EHA

Roche doubles down on BTK with $2.3bn Nurix deal

New data build case for Roche's oral BTK drug for MS

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

BTK inhibitor

Editor's Picks